Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 41%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Eli Lilly reported a robust performance in its second quarter of 2025, surpassing expectations for both revenue and earnings while also raising its full-year guidance. Notably, sales of Mounjaro outside the U.S. experienced a remarkable 60% quarter-over-quarter growth, attributed to successful launches in new markets such as Brazil, Mexico, and India. Additionally, the introduction of orforglipron presents an appealing oral option for patients seeking weight loss solutions, further positioning Lilly to expand its presence in the GLP-1 market.

Bears say

Eli Lilly faces significant downside risks, including potential pricing pressure and an unfavorable prescription trajectory for tirzepatide, which could adversely impact revenue growth. The negative performance of Zepbound prescriptions and expectations for sluggish volumetric growth in Q3 add to the company's challenges. Additionally, the emergence of competitive products like orforglipron, which has demonstrated strong efficacy, further complicates Lilly's market position and could hinder future sales projections.

Eli Lilly (LLY) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 41% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 17 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,086.76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,086.76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.